Share on StockTwits

Pacira Pharmaceuticals (NASDAQ:PCRX) is scheduled to post its quarterly earnings results on Thursday, July 31st. Investors that wish to listen to the company’s conference call can do so using this link.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, May 1st. The company reported ($0.19) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.32) by $0.13. The company had revenue of $36.70 million for the quarter, compared to the consensus estimate of $35.40 million. The company’s quarterly revenue was up 216.4% on a year-over-year basis. On average, analysts expect Pacira Pharmaceuticals to post $-0.52 EPS for the current fiscal year and $1.98 EPS for the next fiscal year.

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 1.16% on Wednesday, hitting $88.34. 29,745 shares of the company’s stock traded hands. Pacira Pharmaceuticals has a 1-year low of $30.75 and a 1-year high of $94.30. The stock’s 50-day moving average is $86.82 and its 200-day moving average is $74.96. The company’s market cap is $3.150 billion.

A number of analysts have recently weighed in on PCRX shares. Analysts at Bank of America reiterated a “positive” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, July 17th. On the ratings front, analysts at Barclays raised their price target on shares of Pacira Pharmaceuticals from $85.00 to $107.00 in a research note on Wednesday, July 16th. They now have an “overweight” rating on the stock. Finally, analysts at Canaccord Genuity initiated coverage on shares of Pacira Pharmaceuticals in a research note on Friday, June 27th. They set a “buy” rating and a $109.00 price target on the stock. They noted that the move was a valuation call. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $87.68.

Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.